Nordea Investment Management AB increased its stake in Omnicell, Inc. (NASDAQ:OMCL – Get Rating) by 3.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 101,857 shares of the company’s stock after purchasing an additional 3,048 shares during the period. Nordea Investment Management AB owned approximately 0.23% of Omnicell worth $4,996,000 as of its most recent SEC filing.
A number of other institutional investors also recently made changes to their positions in the business. Exchange Traded Concepts LLC raised its position in Omnicell by 1,722.2% during the 4th quarter. Exchange Traded Concepts LLC now owns 376,492 shares of the company’s stock valued at $18,983,000 after purchasing an additional 355,831 shares in the last quarter. Lazard Asset Management LLC raised its stake in shares of Omnicell by 24.1% in the third quarter. Lazard Asset Management LLC now owns 1,097,358 shares of the company’s stock worth $95,502,000 after purchasing an additional 212,817 shares during the last quarter. Scout Investments Inc. raised its holdings in shares of Omnicell by 58.3% during the fourth quarter. Scout Investments Inc. now owns 490,893 shares of the company’s stock worth $24,751,000 after purchasing an additional 180,848 shares during the last quarter. Trillium Asset Management LLC raised its position in Omnicell by 50.4% during the fourth quarter. Trillium Asset Management LLC now owns 451,253 shares of the company’s stock valued at $22,752,000 after acquiring an additional 151,223 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH increased its holdings in Omnicell by 133.9% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 253,033 shares of the company’s stock valued at $12,758,000 after buying an additional 144,830 shares in the last quarter.
Wall Street Analysts Forecast Growth
A number of analysts have commented on the stock. TheStreet downgraded shares of Omnicell from a “c” rating to a “d+” rating in a report on Tuesday, February 28th. StockNews.com started coverage on shares of Omnicell in a report on Thursday, March 16th. They issued a “hold” rating for the company. SVB Leerink reissued a “market perform” rating on shares of Omnicell in a report on Friday, January 27th. KeyCorp upped their price objective on shares of Omnicell from $65.00 to $70.00 in a report on Wednesday, May 3rd. Finally, Wells Fargo & Company lowered their price objective on Omnicell from $71.00 to $65.00 and set an “overweight” rating for the company in a research report on Tuesday, January 24th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Omnicell has an average rating of “Moderate Buy” and a consensus target price of $72.22.
Insider Transactions at Omnicell
Omnicell Price Performance
NASDAQ OMCL opened at $67.06 on Thursday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.06 and a quick ratio of 1.75. Omnicell, Inc. has a 52-week low of $46.11 and a 52-week high of $125.17. The company has a 50 day simple moving average of $58.57 and a 200-day simple moving average of $55.77. The firm has a market capitalization of $3.02 billion, a price-to-earnings ratio of -167.65, a price-to-earnings-growth ratio of 9.41 and a beta of 0.90.
Omnicell (NASDAQ:OMCL – Get Rating) last issued its quarterly earnings results on Tuesday, February 28th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.20. Omnicell had a positive return on equity of 5.38% and a negative net margin of 1.39%. The firm had revenue of $297.67 million for the quarter, compared to analyst estimates of $286.32 million. Equities research analysts predict that Omnicell, Inc. will post 0.5 earnings per share for the current fiscal year.
Omnicell Profile
Omnicell, Inc engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation.
Featured Stories
- Get a free copy of the StockNews.com research report on Omnicell (OMCL)
- Occidental Petroleum: Will Buffet Buy More?
- 5 Best Healthcare Sector ETFs
- Electronic Arts Has Game But Can Share Price Move Higher?
- Wendy’s May Have Just Become A Value Play
- Rivian Leads EV Startups But Will The Stock Move Higher?
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.
